Endonovo
Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive
Electroceutical® therapeutic devices, has completed clinical trials and is
currently expanding commercialization of its SofPulse® device that delivers
pulsed electromagnetic frequencies for pain management. An article discussing
the company reads, “In August, Endonovo announced its Q2 financial results, showing
growth in both revenue and gross profits. However, since the economic potential
for a safe, nonaddictive alternative to opioids is significant, the company’s
continued progress as it reaches developmental and test milestones is clearly
the key focus. Over the second quarter of 2019, the company expanded SofPulse®
commercialization and announced the first commercial sales of the device for
post-operative pain and edema. ‘The opioid epidemic is a major issue in society
today, making SofPulse® a significant alternative to postoperative pain
management. We believe we have laid the foundation for rapid growth and
expansion,’ Endonovo CEO Alan Collier said in a company news release (http://ibn.fm/F4JX0).”
To view the full article, visit http://ibn.fm/3EUv0
About Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of
noninvasive, wearable Electroceuticals® therapeutic devices. The company’s current
portfolio of commercial and clinical-stage wearable Electroceuticals®
therapeutic devices addresses wound healing, pain, postsurgical pain and edema,
cardiovascular disease, chronic kidney disease, and central nervous system
(“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions,
postconcussion syndrome and multiple sclerosis. The company’s noninvasive
Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave
radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the
palliative treatment of soft-tissue injuries and postoperative pain and edema
and has CMS national coverage for the treatment of chronic wounds. The
company’s current portfolio of preclinical-stage Electroceuticals® therapeutic
devices addresses chronic kidney disease, liver-disease nonalcoholic
steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and
ischemic stroke. The company’s noninvasive, wearable Electroceuticals®
therapeutic devices work by restoring key electrochemical processes that
initiate anti-inflammatory and growth-factor cascades necessary for healing to
occur. For more information, visit the company’s website at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates
relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment